Roivant Sciences (ROIV) Expected to Announce Quarterly Earnings on Monday

Roivant Sciences (NASDAQ:ROIV - Get Free Report) is anticipated to announce its earnings results before the market opens on Monday, February 10th. Analysts expect the company to announce earnings of ($0.24) per share and revenue of $4.75 million for the quarter. Individual that are interested in registering for the company's earnings conference call can do so using this link.

Roivant Sciences Stock Down 0.9 %

ROIV traded down $0.10 on Thursday, reaching $10.87. The company's stock had a trading volume of 4,922,686 shares, compared to its average volume of 4,151,360. The stock has a 50 day moving average of $11.58 and a two-hundred day moving average of $11.60. The company has a market capitalization of $7.91 billion, a price-to-earnings ratio of 1.92 and a beta of 1.25. Roivant Sciences has a fifty-two week low of $9.76 and a fifty-two week high of $13.06.

Insider Buying and Selling

In other Roivant Sciences news, CIO Mayukh Sukhatme sold 412,584 shares of Roivant Sciences stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $12.05, for a total transaction of $4,971,637.20. Following the sale, the executive now directly owns 18,836,547 shares of the company's stock, valued at approximately $226,980,391.35. The trade was a 2.14 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Eric Venker sold 100,000 shares of the stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $11.32, for a total value of $1,132,000.00. Following the sale, the chief operating officer now owns 606,525 shares in the company, valued at approximately $6,865,863. This trade represents a 14.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,942,629 shares of company stock valued at $23,034,486. Corporate insiders own 7.90% of the company's stock.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Cantor Fitzgerald upgraded shares of Roivant Sciences to a "strong-buy" rating in a research note on Thursday, January 30th. HC Wainwright reissued a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $17.93.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.